🔥 Trending Mounjaro and GLP-1 Drugs Linked to Rare Eye Disorder: What You Need to Know

Recent safety warnings have highlighted a rare but severe eye disorder linked to GLP-1 receptor agonist (GLP-1 RA) medications, which include popular drugs like Mounjaro, Ozempic, Wegovy, and Zepbound ¹²³⁴⁸.

The Specific Eye Disorder

The eye disorder identified is non-arteritic anterior ischaemic optic neuropathy (NAION) ⁷.

What is NAION?

NAION is a condition that can cause sudden vision loss ⁷. It occurs when there is insufficient blood flow to the optic nerve, which is responsible for transmitting visual information from the eye to the brain ⁶. This lack of blood flow can damage the optic nerve, leading to impaired vision, potentially including blindness ⁷.

Link to GLP-1 RA Medications

Regulatory bodies, such as the Therapeutic Goods Administration (TGA) in Australia, have updated product warnings for GLP-1 RA medications due to this potential risk ³⁴. As of July 2026, the TGA reported 36 cases of eye disorders linked to these medications in Australia ¹. A study from Rutgers also suggested that GLP-1 drugs might slightly increase the risk of NAION ⁶.

Medications Involved

The warning specifically applies to the class of GLP-1 RA medications, which are primarily used for managing type 2 diabetes mellitus and, in some cases, obesity ³⁵. These include:

• Mounjaro (tirzepatide) ¹⁴⁶⁸
• Ozempic (semaglutide) ¹²⁴⁶⁸
• Wegovy (semaglutide) ¹²⁴⁶⁸
• Zepbound (tirzepatide) ⁶⁸

Symptoms to Watch For

Patients taking these medications are urged to be vigilant for any signs of sudden vision loss or impairment ⁷. While the absolute risk is considered small, it is crucial for individuals to be aware of the potential symptoms and to seek immediate medical attention if they experience any changes in their vision ⁶⁷.

Distinction from Other Vision Changes

It's important to differentiate this severe condition from other, more common and temporary vision changes that can occur with GLP-1 RA medications. For instance, some individuals may experience blurred vision when starting semaglutide (Ozempic/Wegovy). This is often related to rapid changes in blood glucose levels, which can affect the shape of the eye's lens ⁹¹⁰. This type of blurred vision is typically a temporary side effect and is distinct from the permanent vision loss associated with NAION.

While the link to NAION is considered rare, patients on GLP-1 RA drugs should discuss any vision concerns with their healthcare providers ¹⁶.